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Abstract
Background: The XANTUS study (NCT01606995) demonstrated low rates of stroke
and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in
clinical practice for the prevention of thromboembolic events (N = 6784).
Hypothesis: Because previous real-world studies have not reported gender-
dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS
study investigated the effect of gender on outcomes.
Methods: The centrally adjudicated outcomes were compared between genders.
Primary outcomes were major bleeding and all-cause death. Secondary outcomes
included symptomatic thromboembolic events. Multivariable Cox regression analysis
was performed to assess the effect of risk factors on outcomes between genders.
Results: A total of 2765 female and 4016 male patients were included in the analysis.
Baseline characteristics were generally similar. No nominally significant interaction
between gender and risk factors for the study outcomes was observed. Rates of
major bleeding, all-cause death and symptomatic thromboembolic events in patients
with non-valvular AF receiving rivaroxaban for stroke prevention were similar in men
and women; no significant differences in risk factors for these outcomes were
observed between genders.
Conclusions: Further research is needed to better characterize the relative impor-
tance of different risk factors on outcomes in men vs women and to determine
whether gender differences exist in patients treated with non-vitamin K antagonist
oral anticoagulants.
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1 | INTRODUCTION
Atrial fibrillation (AF) is a common cardiac arrhythmia.1 Its reported
prevalence has increased in recent years, due to the aging population
and perhaps partly due to improved detection.1,2 AF is associated with
a 5-fold increase in the risk of stroke. The risk of AF is higher in men
than women, with a ratio of 1.2:1.3 According to data from the
Framingham Heart Study, the prevalence of AF in men is nearly twice
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that in women when adjusting for age.4 However, because the preva-
lence of AF increases with age and, on average, women live longer
than men, it is estimated that at least as many women as men have
AF.5,6 In contrast, women with AF have a higher risk of stroke than
men with AF, and AF-related strokes appear to be more severe in
women.7,8 Female gender is a recognized risk factor in the CHA2DS2-
VASc stroke risk stratification scheme.1,7
XANTUS was an international, prospective, observational study
designed to assess the safety and effectiveness of rivaroxaban for
stroke prevention in routine clinical practice in patients with non-
valvular AF newly initiated on rivaroxaban (N = 6784).9 In this study,
patients taking rivaroxaban had low rates of stroke and major bleed-
ing; most patients (96.1%) did not experience a major event (major
bleeding, death or stroke/systemic embolism [SE]) during the study.9
There is some evidence that gender-dependent responses to anti-
coagulant treatment may exist, such as a smaller reduction in stroke/
SE risk with anticoagulation in women compared with men.10 Because
this could have important clinical implications, we performed an analy-
sis of the XANTUS data to investigate the impact of gender on the
rates of major bleeding, symptomatic thromboembolic events and
death in patients with AF receiving rivaroxaban in clinical practice.
2 | METHODS
The design of the international, noninterventional, observational
XANTUS study was approved by the European Medicines Agency.
The study design and main results have been published previ-
ously.9,11 Briefly, men and women (aged ≥18 years) with AF initiated
on rivaroxaban therapy for stroke/SE prevention were enrolled.
Patients had follow-up visits at approximately 3month intervals for
1 year; or approximately 30 days after permanent discontinuation of
rivaroxaban, if treatment was discontinued before 1 year.
Primary outcomes were chosen to assess the safety of
rivaroxaban in clinical practice and consisted of major bleeding events
(International Society on Thrombosis and Haemostasis definition12)
and all-cause death. Secondary outcomes included symptomatic
thromboembolic events: stroke, noncentral nervous system SE (non-
CNS SE), transient ischemic attack (TIA) and myocardial infarction.
These outcomes were adjudicated by a Central Adjudication
Committee.
The analyses were based on the safety population, which
included all patients who received at least one dose of rivaroxaban.
Only treatment-emergent events were included in the analyses. An
event was considered treatment emergent if it occurred on or after
the day of the first dose of rivaroxaban and up to 2 days after the last
dose. No imputation of missing data was applied, that is, patients with
missing data for the variables required for multivariable Cox regres-
sion modeling were not included in the analyses. However, a large
proportion of patients (34.4%) had missing creatinine clearance (CrCl)
measurements. Because the rates of treatment-emergent major out-
comes were lower in patients with missing CrCl data (compared with
patients with available CrCl measurements) and their baseline
characteristics were similar to those of patients with CrCl ≥50 mL/
minute, these patients were included in the analysis by grouping them
with patients with CrCl ≥50 mL/minute.
To identify differences in the influence of risk factors on out-
comes between genders, a multivariable Cox regression model was
fitted; it included the risk factors of interest as well as gender interac-
tions. Based on this model, the effect of risk factors on outcomes was
displayed separately for women and men, with interaction P values
indicated. Risk factors for each outcome were selected based on med-
ical judgment, and included risk factors in the CHADS2, HAS-BLED,
and CHA2DS2-VASc scores as well as risk factors identified in previ-
ous studies.10 This sub-analysis was of an exploratory, descriptive
nature. Hazard ratios (HRs) with 95% confidence intervals (CIs) were
calculated before and after adjusting for differences in baseline risk
factors to explore directional trends.
3 | RESULTS
Of the 6784 patients included in the safety population, 4016 (59.2%),
were male and 2765 (40.8%) were female. On average, women were
older than men (mean 73.7 vs 70.0 years old, respectively; P < .0001),
and more women were aged >75 years (46.3% vs 30.9%; P < .0001)
(Table 1). Compared with men, women had higher risk scores for
stroke (mean CHADS2 score 2.1 vs 1.9 in men; P < .0001) and bleed-
ing (mean HAS-BLED score 2.1 vs 2.0 in men; P < .0001), as well as
higher rates of hypertension (77.0% vs 73.1% in men; P = .0002). The
mean CHA2DS2-VASc score was 4.1 in women and 2.9 in men
(P < .0001). However, being female adds one point to this score: after
excluding gender, the mean CHA2DS2-VASc scores were 3.1 for
women and 2.9 for men (P < .0001). Because female gender
accounted for most of the difference in CHA2DS2-VASc score, it is
unlikely that other factors such as age > 75 years contributed sub-
stantially to the difference in CHA2DS2-VASc score between men and
women.
Some differences in baseline co-morbidities were apparent
between men and women (Table 1): women were more likely to have
a history of stroke/TIA/nonCNS SE (20.7% vs 17.9% in men;
P = .0050), but fewer had diabetes (18.0% of women vs 20.8% of
men; P = .0038) or a history of myocardial infarction (6.2% of women
vs 12.8% of men; P < .0001). Similar proportions of women (66.2%)
and men (65.2%) had available CrCl measurements (first available
CrCl, Table 1). Among patients with available CrCl measurements,
more women than men had moderate-to-severe renal impairment
(CrCl <50 mL/minute; 13.2% of women vs 6.9% of men), qualifying
them for a reduced dose of rivaroxaban according to the label recom-
mendation.13 A total of 3279 men (81.6%) and 2054 women (74.3%)
received rivaroxaban 20 mg once daily, while 717 men (17.9%) and
693 women (25.1%) received a reduced dose of rivaroxaban 15 mg
once daily. Less than 1% of patients received other or unknown
doses.
Before adjusting for baseline differences, men and women had a
similar risk of major bleeding (HR = 1.18 for men vs women; 95% CI
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TABLE 1 Baseline characteristics of patients treated with rivaroxaban in XANTUS with available data relating to gender
Baseline characteristic Men(n = 4016) Women(n = 2765) P Valuea
Age, years, mean ± SD 70.0 ± 10.0 73.7 ± 9.5 <.0001
<.0001<65 y, n (%) 1051 (26.2) 427 (15.4)
≥65-≤ 75 y, n (%) 1723 (42.9) 1058 (38.3)
>75 y, n (%) 1242 (30.9) 1280 (46.3)
First available weight, kg, mean ± SD 88.6 ± 16.3 74.8 ± 15.4 <.0001
Body mass index, mean ± SD 28.5 ± 4.6 28.0 ± 5.5 .0004
First available creatinine clearance, n (%) <.0001
<15 mL/minute 12 (0.3) 8 (0.3)
15 to < 30 mL/minute 32 (0.8) 43 (1.6)
≥30 to < 50 mL/minute 232 (5.8) 313 (11.3)
≥50 to ≤ 80 mL/minute 1331 (33.1) 1022 (37.0)
>80 mL/minute 1013 (25.2) 444 (16.1)
Data missing 1396 (34.8) 935 (33.8)
Existing co-morbidities, n (%)
Hypertension 2934 (73.1) 2129 (77.0) .0002
Diabetes 836 (20.8) 497 (18.0) .0038
Congestive heart failure 753 (18.8) 512 (18.5) .8089
Prior stroke/TIA/nonCNS SE 720 (17.9) 571 (20.7) .0050
Prior myocardial infarction 516 (12.8) 172 (6.2) <.0001
Vascular diseaseb 1109 (27.6) 576 (20.8) <.0001
Type of atrial fibrillation, n (%) <.0001
First diagnosed 728 (18.1) 524 (19.0)
Paroxysmal 1537 (38.3) 1218 (44.1)
Persistent 601 (15.0) 322 (11.6)
Permanent 1144 (28.5) 691 (25.0)
Data missing 6 (0.1) 10 (0.4)
CHADS2 score, mean ± SD 1.9 (1.3) 2.1 (1.3) <.0001
CHA2DS2-VASc score, mean ± SD 2.9 (1.6) 4.1 (1.6) <.0001
HAS-BLED score, mean ± SD 2.0 (1.0) 2.1 (1.0) <.0001
Prior antithrombotic therapy, n (%) .0006
Yes 2998 (74.7) 1960 (70.9)
No 1018 (25.3) 805 (29.1)
Type of prior antithrombotic therapy, n (%) .0046
Vitamin K antagonist 1649 (41.1) 1118 (40.4)
Direct thrombin inhibitor 122 (3.0) 86 (3.1)
Direct Factor Xa inhibitor 8 (0.2) 2 (0.1)
Acetylsalicylic acid 744 (18.5) 479 (17.3)
Dual antiplatelet therapy 51 (1.3) 17 (0.6)
Heparin 130 (3.2) 87 (3.1)
Other antithrombotic therapy 36 (0.9) 19 (0.7)
Multiple 258 (6.4) 152 (5.5)
Hospitalized at baseline, n (%) .042
Yes 689 (17.2) 537 (19.4)
No 3326 (82.8) 2228 (80.6)
Data missing 1 (< 0.05) 0 (0.0)
Abbreviations: NonCNS SE, noncentral nervous system systemic embolism; SD, standard deviation; TIA, transient ischemic attack.
aBased on chi-square test for categorical variables and t-test for continuous variables.
bDefined as peripheral artery disease, ischemic heart disease or cerebrovascular disease.
CAMM ET AL. 3
Outcome
Men (N = 4016) Women (N = 2765)
aHR 95% CI p Value
n (%)
Events/100 
Patient-
Years 
(95% CI)
n (%)
Events/100 
Patient-
Years
(95% CI)
Major bleeding 81(2.0)
2.2
(1.8–2.8)
47
(1.7)
1.9
(1.4–2.5) 1.39* 0.96–2.01 .080
Stroke/non-CNS SE 29 
(0.7)
0.8
(0.5–1.1)
22 
(0.8)
0.9
(0.6–1.3)
1.04† 0.59–1.84 .893
All-cause death 66 
(1.6)
1.8
(1.4–2.3)
52 
(1.9)
2.1 
(1.6–2.7) 1.07
‡ 0.73–1.58
Composite outcome 
(major bleeding, 
stroke/non-CNS SE 
or all-cause death)
152
(3.8)
4.2
(3.6–4.9)
112
(4.1)
4.5 
(3.7–5.5) 1.11
§ 0.85–1.43 .442
Myocardial infarction 18(0.4)
0.5
(0.3–0.8)
9
(0.3)
0.4
(0.2–0.7) 1.17
¶ 0.51–2.68 .718
0.1 1 10
Higher risk in women Higher risk in men
aHR (95% CI)
.713
F IGURE 1 Adjusted outcomes by gender*Adjusted for age, first available CrCl, CHF, uncontrolled hypertension, prior stroke/TIA/nonCNS SE,
prior bleeding, vascular disease, liver disease and baseline antiplatelets/acetylsalicylic acid/nonsteroidal anti-inflammatory drugs; †adjusted for
age, first available CrCl, CHF, hypertension, prior stroke/TIA/nonCNS SE, vascular disease and diabetes mellitus; ‡adjusted for age, first available
CrCl, CHF, hypertension, prior stroke/TIA/nonCNS SE, vascular disease, diabetes mellitus and current smoker; §adjusted for age, first available
CrCl, CHF, hypertension, prior bleeding, prior stroke/TIA/nonCNS SE, vascular disease, diabetes mellitus, current smoker, baseline antiplatelets/
acetylsalicylic acid/nonsteroidal anti-inflammatory drugs and liver disease; ¶adjusted for age, hypertension, vascular disease, diabetes mellitus and
current smoker aHR, adjusted hazard ratio (men vs women); CHF, congestive heart failure; CI, confidence interval; CrCl, creatinine clearance; HR,
hazard ratio; nonCNS SE, noncentral nervous system systemic embolism; TIA, transient ischemic attack
Men Women
Major Bleeding
HR (95% CI) HR 95% CI
p Value for 
Interaction*
Age (years) .561
65–75 vs < 65
2.54 1.16–5.56
1.21 0.39–3.73
> 75 vs < 65
4.26 1.98–9.19
2.22 0.77–6.45
First available CrCl:
≥ 50 ml/min (or missing) vs < 50 ml/min
0.58 0.31–1.06 .389
0.88 0.41–1.88
Congestive heart failure: 
Yes vs no
2.57 1.63–4.05 .089
1.27 0.65–2.48
Uncontrolled hypertension:  
Yes vs no
1.86 0.75–4.63 .798
1.53 0.47–4.98
Prior stroke/TIA/non-CNS SE: 
Yes vs no
0.74 0.41–1.34 .175
1.36 0.71–2.57
Vascular disease: 
Yes vs no
2.06 1.31–3.24 .660
1.72 0.91–3.28
Liver disease:
Yes vs no
1.43 0.45–4.59 .476
2.63 0.78–8.84
Baseline antiplatelet/ASA/NSAID:
Yes vs no
0.75 0.42–1.35 .819
0.85 0.36–2.01
0.1 1 10
F IGURE 2 Influence of risk factors on major bleeding by gender *P value is based on the interaction between gender and the individual risk
factor. ASA, acetylsalicylic acid; CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; nonCNS SE, noncentral nervous system
systemic embolism; NSAID, nonsteroidal anti-inflammatory drug; TIA, transient ischemic attack
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0.82-1.69; P = .368), stroke/nonCNS SE (HR = 0.90; 95% CI 0.52-
1.57; P = .714), all-cause death (HR = 0.87; 95% CI 0.60-1.25;
P = .449), the composite of major bleeding, all-cause death, stroke or
nonCNS SE (HR = 0.93; 95% CI 0.73-1.18; P = .539), myocardial
infarction (HR = 1.37; 95% CI 0.62-3.05; P = .440) or ischemic stroke
(HR = .68; 95% CI 0.34-1.37; P = .284).
After adjustment for differences in baseline risk factors, men and
women still had similar risks of all major outcomes (Figure 1). There
was a nonsignificant trend towards a higher risk of major bleeding in
men compared with women (HR = 1.39; 95% CI 0.96-2.01; P = .080).
The risk of stroke/nonCNS SE (HR 1.04; 95% CI 0.59-1.84; P = .893)
and all-cause death (HR = 1.07; 95% CI 0.73-1.58; P = .713) were
similar between genders. Finally, there were no nominally significant
differences between genders in the risk of the composite of major
bleeding, all-cause death, stroke or nonCNS SE (HR = 1.11; 95% CI
0.85-1.43; P = .442) or the individual outcomes of myocardial infarc-
tion (HR = 1.17; 95% CI 0.51-2.68; P = .718) or ischemic stroke
(HR = 0.79; 95% CI 0.39-1.61; P = .518).
Analysis of the influence of different risk factors on major bleed-
ing, stroke/SE, all cause-death and the composite outcome revealed
Men Women
HR
(A)
(B)
p Value for
Interaction*
Age (years) .055
65–75 vs < 65
1.91 0.69–5.31
0.75 0.14–4.10
> 75 vs < 65
1.26 0.41–3.88
2.74 0.62–12.11
0.57 0.19–1.69 .113
2.49 0.57–10.85
3.69 1.75–7.77 .210
1.73 0.69–4.33 
Hypertension: 
Yes vs no
2.07 0.71–6.03 .897
2.34 0.54–10.22
2.55 1.19–5.46 .384
1.50 0.60–3.76
Vascular disease: 
Yes vs no
1.32 0.61–2.85 .365
0.73 0.26–2.05
Diabetes:
Yes vs no
0.72 0.29–1.81 .055
2.51 1.04–6.09 
0.1 1 10
Stroke/Non-CNS SE
HR (95% CI) 95% CI
First available CrCl:
≥ 50 ml/min (or missing) vs < 50 ml/min
Congestive heart failure: 
Yes vs no
Prior stroke/TIA/non-CNS SE: 
Yes vs no
Men Women
HR 95% CI
Age (years) .203
65–75 vs < 65
1.05 0.50–2.22
0.34 0.12–0.93
> 75 vs < 65
1.87 0.92–3.82
1.12 0.49–2.51
First available CrCl: 
≥ 50 ml/min (or missing) vs < 50 ml/min
0.36 0.20–0.66
0.50 0.26–0.95
Congestive heart failure: 
Yes vs no
3.29 1.99–5.42
2.58 1.43–4.67
Hypertension: 
Yes vs no
0.78 0.44–1.37
0.92 0.46–1.82
1.48 0.85–2.58
1.44 0.77–2.69
Vascular disease: 
Yes vs no
1.72 1.03–2.88
0.76 0.37–1.54
Diabetes mellitus: 
Yes vs no
1.47 0.86–2.51
1.06 0.53–2.15
Current smoker:
Yes vs no
0.59 0.18–1.91
1.38 0.33–5.80
0.1 1 10
Prior stroke/TIA/non-CNS SE: 
Yes vs no
All-Cause Death
HR (95% CI)
p Value for
Interaction*
.457
.544
.721
.958
.068
.477
.371
F IGURE 3 Influence of risk factors on A, stroke/nonCNS SE by gender and B, all-cause death by gender*P value is based on the interaction
between gender and the individual risk factor. CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; nonCNS SE, noncentral
nervous system systemic embolism; TIA, transient ischemic attack
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broadly consistent results between genders. Several nonsignificant
trends were observed. Advancing age and congestive heart failure
(CHF) tended to be associated with a greater increase in the risk of
major bleeding in men than in women, while a history of vascular
disease was associated with a nonsignificant increase in the risk of
major bleeding in both genders (Figure 2).
No significant interactions were found between gender and risk
factors for stroke/SE (Figure 3A). In women, but not men, advancing age
tended to increase the risk of stroke/SE, while CHF tended to increase
the risk of stroke/SE to a greater extent in men than in women. In
women, there was a nonsignificant increase in the risk of stroke/SE for
those with diabetes mellitus compared with those without; in contrast,
in men there was a nonsignificant decrease in risk of stroke/SE for those
with diabetes mellitus compared with those without diabetes.
CHF was an equally important risk factor for death in men and
women (Figure 3B), while the risk of death in patients with vascular
disease appeared to be nonsignificantly elevated in men but not
women. In addition, CHF and advancing age (> 75 years vs < 65 years)
were potential risk factors for the composite outcome of major bleed-
ing, stroke/nonCNS SE or death in both genders, while vascular disease
and liver disease were associated with a nonsignificant increase in the
risk of the composite outcome in men but not women (Figure 4).
4 | DISCUSSION
This XANTUS sub-analysis showed that, in this cohort of rivaroxaban-
treated patients with AF, gender did not affect outcomes and the
influence of different risk factors on outcomes was broadly similar
between men and women.
At baseline, women were more likely than men to have a history
of stroke/TIA/SE, perhaps partly due to their higher mean age. How-
ever, these rivaroxaban-treated women were not at higher risk of
stroke/SE than men, which is at odds with the inclusion of female
gender as a risk factor in the CHA2DS2-VASc scoring system.
14 Based
on the literature, however, there are contradictory data regarding the
influence of female gender on stroke risk. In a recent review of
30 studies published since 1999, 17 studies identified female gender
as a significant risk factor for stroke, whereas 12 of the remaining
13 studies reporting no differences in stroke risk between men and
women.15 Meta-analyses that predominantly included data from
cohort studies have reported women to have a 1.3- to 2-fold higher
risk of stroke compared with men.7,16 In our study, the similar risk of
stroke/SE in both genders could also indicate greater effectiveness of
rivaroxaban in women compared with men. Because all patients in the
study received rivaroxaban treatment, this cannot be assessed by
comparison with a control group.
Contemporary prospective registry data report disparate findings
on the influence of gender on stroke outcomes; whereas data from
the multinational GARFIELD AF and the US-based ORBIT AF regis-
tries show a 1.3- to 1.4-fold higher risk of stroke/SE in women com-
pared with men after adjustments for baseline characteristics, in the
European PREFER-in-AF registry, men and women had a similar age-
and country-adjusted risk of ischemic stroke/TIA/arterial embolism at
1-year follow-up. In all three of the aforementioned registries, antico-
agulant use at baseline was similar between men and women.10,17,18
Men Women
HR 95% CI
Age (years) .203
65–75 vs < 65
1.05 0.50–2.22
0.34 0.12–0.93
> 75 vs < 65
1.87 0.92–3.82
1.12 0.49–2.51
First available CrCl: 
≥ 50 ml/min (or missing) vs < 50 ml/min
0.36 0.20–0.66
0.50 0.26–0.95
Congestive heart failure: 
Yes vs no
3.29 1.99–5.42
2.58 1.43–4.67
Hypertension: 
Yes vs no
0.78 0.44–1.37
0.92 0.46–1.82
1.48 0.85–2.58
1.44 0.77–2.69
Vascular disease: 
Yes vs no
1.72 1.03–2.88
0.76 0.37–1.54
Diabetes mellitus: 
Yes vs no
1.47 0.86–2.51
1.06 0.53–2.15
Current smoker:
Yes vs no
0.59 0.18–1.91
1.38 0.33–5.80
0.1 1 10
Prior stroke/TIA/non-CNS SE: 
Yes vs no
All-Cause Death
HR (95% CI)
p Value for
Interaction*
.457
.544
.721
.958
.068
.477
.371
F IGURE 4 Influence of risk factors on the composite outcome of major bleeding, all-cause death, stroke or nonCNS SE by gender *P value is
based on the interaction between gender and the individual risk factor. ASA, acetylsalicylic acid; CI, confidence interval; CrCl, creatinine
clearance; HR, hazard ratio; nonCNS SE, noncentral nervous system systemic embolism; NSAID, nonsteroidal anti-inflammatory drug; TIA,
transient ischemic attack
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Consistent with the results of this XANTUS analysis, a meta-analysis
of phase III data from the RE-LY, ROCKET AF, AVERROES and ARIS-
TOTLE trials reported that, in patients receiving non-vitamin K antag-
onist oral anticoagulants, the risk of stroke/SE was similar between
men and women. In the same meta-analysis, data from patients
treated with vitamin K antagonists in the SPORTIF III-IV, RE-LY, ARIS-
TOTLE, ROCKET AF and BAFTA trials showed that the risk of stroke/
SE was higher in women than men.19 Interestingly, in GARFIELD AF,
anticoagulation (which consisted of vitamin K antagonists in about
73% of patients treated, irrespective of gender) appeared to be less
effective at reducing the risk of stroke/SE in women than in men.10
Together, these data suggest that gender differences in stroke risk
may be more pronounced with vitamin K antagonists than non-
vitamin K antagonist oral anticoagulants. The reasons for this are
unclear, but may reflect poorer vitamin K antagonist control in women
compared with men - indeed, female gender is included as a risk factor
in the SAMe-TT2R2 score, which can predict poor international nor-
malized ratio control.20 Further research is needed to investigate
TABLE 2 Summary of studies assessing the effect of gender on outcomes in patients with atrial fibrillation
Study
Population agea and gender
distribution
Reported effect of gender on outcome(s)b
Stroke/SE Major bleeding Mortality
Randomized controlled trials
Subanalysis of risk factors
for major bleeding in
ROCKET AF24
Median age 73 years, IQR
65,78
40% female patients
NR Lower risk in women NR
Subanalysis of risk factors
for major bleeding in
ARISTOTLE25,26
Median age 70 years, IQR
63,76
35% female patients
NR Lower risk in women NR
Observational studies
Prospective GARFIELD-AF
registry study10
Mean age 72 ± 10.4 years
in women and
68 ± 11.7 years in men
44% female patients
Higher risk in womenc No significant differencec No significant
differencec
Prospective ORBIT AF
registry study17
Median age 77 (69,83)
years in women and 73
(65,80) years in men
42% female patients
Higher risk in womenc No significant difference Lower risk in women
(all-cause and CV
death)c
Prospective PREFER
registry study18
Mean age 70 ± 10.7 years
in men and
74 ± 9.7 years in
women
40% female patients
No significant differencec No significant differencec NR
Reviews and meta-analyses
Review of 30
observational and
randomized controlled
trials15
Overall age and gender
distribution in patients
with AF not reported
Higher risk in women (17
studies); no significant
difference (12 studies);
higher risk in men (one
study)
NR NR
Meta-analysis of 30
cohort studies7
Age 45 to 83 years
Overall proportion of
female patients with AF
not reported
Higher risk in women NR Higher risk in women
(all-cause and CV
death)
Meta-analysis of five
randomized controlled
trials and 12 prospective
observational studies9
Mean age 62 to 83 years
28% to 53% female
patients
Higher risk in women NR NR
Meta-analysis of six
randomized controlled
trials19
Mean age 70 to 81 years
Overall proportion of
female patients not
reported
No significant difference
(with NOACs), or higher
risk in women (with VKA
therapy)
Lower risk in women (with
NOACs), or no difference
between genders (with
VKA therapy)
NR
Abbreviations: AF, atrial fibrillation; CV, cardiovascular; IQR, interquartile range; NOAC, nonvitamin K antagonist oral anticoagulant; NR, not reported; SE,
systemic embolism; TIA, transient ischemic attack; VKA, vitamin K antagonist.
aWhere reported, age is shown as median (IQR) or mean ± SD.
bOutcome definitions may differ between studies.
cAdjusted for differences in baseline characteristics.
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whether gender differences in stroke risk may be influenced by class
of oral anticoagulant.
A recent meta-analysis of data from cohort studies reported a 12%
higher risk of all-cause mortality in women compared with men with
AF.7 However, consistent with data from GARFIELD AF, no differences
in mortality between genders were found in our study. In contrast, in
ORBIT AF, after adjustment for differences in baseline characteristics,
mortality was more than 40% lower in women than men. Gender is not
included as a risk factor for major bleeding in the HAS-BLED, ATRIA or
ORBIT bleeding scores.21-23 Accordingly, data from the GARFIELD AF,
ORBIT AF and PREFER-in-AF registries show no differences in major
bleeding outcomes between women and men.10,17,18 In our study, men
tended to have a higher risk of major bleeding than women, although
this did not reach nominal statistical significance. Nonetheless, this is
broadly consistent with post hoc analyses from ROCKET AF and ARIS-
TOTLE trials, which report female gender to be associated with a lower
risk of major bleeding in multivariate analyses.24,25 A meta-analysis has
also shown women with AF treated with non-vitamin K antagonist oral
anticoagulants have a lower risk of major bleeding than men.19 Because
the ages and gender distributions in the phase III trials, meta-analyses
of phase III trials and registry studies were broadly similar, it is unlikely
that these characteristics contributed substantially to the different
findings of the studies (Table 2).
Our analysis also investigated the influence of different risk fac-
tors on treatment-emergent outcomes in men and women, an
approach used in the GARFIELD AF study to investigate the influence
of gender on outcomes. Although not statistically significant, CHF
was a potential risk factor for death in both genders, consistent with
GARFIELD AF.10 Vascular disease tended to be more often associated
with worse outcomes in men than women, while diabetes tended to
increase the risk of stroke in women, consistent with observations
from a cohort of patients without AF.27 However, trends were not
statistically significant and the low event rates (particularly for the
individual endpoints) resulted in wide confidence intervals, meaning
our findings should be interpreted with caution.
4.1 | Limitations
Enrolment into XANTUS was based on voluntary participation by cen-
ters and patients, which might have created patient or physician selec-
tion bias. Predefined criteria for events and central adjudication are
means to ensure internal validity of the results, but replication in inde-
pendent cohorts is warranted.
Lack of information is a common drawback of real-world studies,
and a limitation of this analysis is the fact that data, such as CrCl
levels, were missing for some patients. Because the baseline charac-
teristics of patients with unknown CrCl were very similar to those
with CrCl >50 mL/minutes, they were included in the same group of
patients. Furthermore, the low burden of cardiovascular disease in the
group with missing CrCl suggests renal impairment is unlikely to be
present in most of these patients. However, the missing CrCl levels in
the current study add some uncertainty to the results.
Additionally, because event rates were generally low, the lack of
differences in the study outcomes between men and women does not
entirely exclude the possibility that there may in fact be some differ-
ences between genders in rivaroxaban-treated patients with AF.
5 | CONCLUSIONS
This XANTUS sub-analysis showed that the rates of major bleeding,
symptomatic thromboembolic events and death in patients with AF
receiving rivaroxaban were similar in men and women; there were no
significant differences in risk factors for these outcomes between gen-
ders. Further research is needed to better characterize the relative
importance of different risk factors on outcomes in men vs women and
to determine whether gender differences exist in patients treated with
vitamin K antagonists or non-vitamin K antagonist oral anticoagulants.
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